Abstract
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract illness in infants and children worldwide, and is an important cause of respiratory illness in the elderly. As of this writing, no licensed RSV vaccines exist, but subunit vaccines containing the RSV F protein in the prefusion conformation are in late-stage clinical development as maternal vaccines to protect the young infant and as vaccines for the elderly. RSV monoclonal antibodies directed at epitopes in RSV prefusion F and containing modifications to increase half-life are also in late stage clinical evaluation to provide passive protection to young infants. Live-attenuated vaccines and mRNA vaccines to provide protection to older infants and toddlers are currently in phase i/ii clinical development.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
